Effects of Flexor Digitorum Longus Muscle Anatomical Structure on the Response to Botulinum Toxin Treatment in Patients with Post-Stroke Claw Foot Deformity

Toxins (Basel). 2022 Sep 25;14(10):666. doi: 10.3390/toxins14100666.

Abstract

(1) Background: The purpose of this retrospective case-control study was to determine the relationship between the control of toe movements by flexor hallucis longus (FHL) and flexor digitorum longus (FDL) muscles and the response to treatment with botulinum toxin (BoNT) in post-stroke patients with claw toe. (2) Methods: Subjects with stroke-related leg paralysis/spasticity and claw toes received multiple injections of BoNT (onabotulinumtoxin A) into the FHL or FDL muscles. We investigated the relationship between the mode of transmission of FHL and FDL muscle tension to each toe (MCT) and treatment outcome using the data of 53 patients who received 124 injections with clinically recorded treatment outcome. We also dissected the potential variables that could determine the treatment outcome. (3) Results: The effectiveness of BoNT treatment was significantly altered by FDL-MCT (OR = 0.400, 95% CI = 0.162-0.987, p = 0.047). Analysis of the response to the first BoNT injection showed an odds ratio of FDL-MCT of approximately 6.0 times (OR = 0.168, 95% CI = 0.033-0.857, p = 0.032). The more tibial the influence of the FDL muscle on each toe, the better the treatment outcome on the claw toe. (4) Conclusions: The anatomic relation between FDL muscle and each toe seems to affect the response to treatment with BoNT in post-stroke patients with claw toes.

Keywords: anatomic variation; cerebrovascular disorders; electric stimulation; flexor digitorum longus; flexor hallucis longus; hammer toe syndrome; muscle contraction.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Botulinum Toxins, Type A* / therapeutic use
  • Case-Control Studies
  • Foot Deformities*
  • Hammer Toe Syndrome*
  • Humans
  • Muscle, Skeletal
  • Retrospective Studies

Substances

  • Botulinum Toxins, Type A

Grants and funding

This work was supported by JSPS KAKENHI Grant Number JP19K20018.